152 related articles for article (PubMed ID: 34607071)
1. Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study.
van der Stoep MYEC; Bertaina A; Moes DJAR; Algeri M; Bredius RGM; Smiers FJW; Berghuis D; Buddingh EP; Mohseny AB; Guchelaar HJ; Locatelli F; Zwaveling J; Lankester AC
Transplant Cell Ther; 2022 Feb; 28(2):99.e1-99.e7. PubMed ID: 34607071
[TBL] [Abstract][Full Text] [Related]
2. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
Huttunen P; Taskinen M; Vettenranta K
Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
[TBL] [Abstract][Full Text] [Related]
3. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
[TBL] [Abstract][Full Text] [Related]
4. Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Galán V; Beléndez C; Echecopar C; Estival P; Sissini L; Olivas R; Bueno D; Molina B; Fuentes C; Regueiro A; Benítez I; Plaza M; Margarit A; Rifón J; Pascual A; Palomo P; Urtasun A; Fuster JL; Díaz de Heredia C; Fernández Navarro JM; González-Vicent M; Ruz B; Pérez-Martínez A
Transplant Cell Ther; 2023 Nov; 29(11):702.e1-702.e11. PubMed ID: 37595686
[TBL] [Abstract][Full Text] [Related]
5. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan- or Busulfan-Based Conditioning in Pediatric Patients with Acute Leukemia or Myelodysplastic Syndrome: Results of an Associazione Italiana Ematologia Oncologia Pediatrica Retrospective Study.
Saglio F; Pagliara D; Zecca M; Balduzzi A; Cattoni A; Prete A; Tambaro FP; Faraci M; Calore E; Locatelli F; Fagioli F;
Transplant Cell Ther; 2024 Apr; 30(4):433.e1-433.e10. PubMed ID: 38176654
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
Olivas-Mazón R; Bueno D; Sisinni L; Mozo Y; Casado-Abad G; Martínez AP
Eur J Haematol; 2022 Nov; 109(5):474-482. PubMed ID: 35810360
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
[TBL] [Abstract][Full Text] [Related]
9. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
[TBL] [Abstract][Full Text] [Related]
10. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.
Boztug H; Zecca M; Sykora KW; Veys P; Lankester A; Slatter M; Skinner R; Wachowiak J; Pötschger U; Glogova E; Peters C;
Ann Hematol; 2015 Feb; 94(2):297-306. PubMed ID: 25231927
[TBL] [Abstract][Full Text] [Related]
11. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
12. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
13. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
14. Effect of Busulfan and Treosulfan on Gonadal Function after Allogeneic Stem Cell Transplantation in Children and Adolescents with Nonmalignant Diseases Is Not Exposure-Dependent.
van der Stoep MYEC; Bense JE; de Kloet LC; von Asmuth EGJ; de Pagter APJ; Hannema SE; Guchelaar HJ; Zwaveling J; Lankester AC
Transplant Cell Ther; 2023 Aug; 29(8):529.e1-529.e5. PubMed ID: 37156421
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
Morillo-Gutierrez B; Beier R; Rao K; Burroughs L; Schulz A; Ewins AM; Gibson B; Sedlacek P; Krol L; Strahm B; Zaidman I; Kalwak K; Talano JA; Woolfrey A; Fraser C; Meyts I; Müller I; Wachowiak J; Bernardo ME; Veys P; Sykora KW; Gennery AR; Slatter M
Blood; 2016 Jul; 128(3):440-8. PubMed ID: 27216217
[TBL] [Abstract][Full Text] [Related]
17. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
18. Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial.
Chiesa R; Standing JF; Winter R; Nademi Z; Chu J; Pinner D; Kloprogge F; McLellen S; Amrolia PJ; Rao K; Lucchini G; Silva J; Ciocarlie O; Lazareva A; Gennery AR; Doncheva B; Cant AJ; Hambleton S; Flood T; Rogerson E; Devine K; Prunty H; Heales S; Veys P; Slatter M
Clin Pharmacol Ther; 2020 Aug; 108(2):264-273. PubMed ID: 31701524
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool.
van der Stoep MYEC; Berghuis D; Bredius RGM; Buddingh EP; Mohseny AB; Smiers FJW; Guchelaar HJ; Lankester AC; Zwaveling J
Sci Rep; 2021 Sep; 11(1):19084. PubMed ID: 34580398
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases.
Slatter MA; Boztug H; Pötschger U; Sykora KW; Lankester A; Yaniv I; Sedlacek P; Glogova E; Veys P; Gennery AR; Peters C;
Bone Marrow Transplant; 2015 Dec; 50(12):1536-41. PubMed ID: 26259076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
